Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Leiden University
Headquarters: Leiden, Netherlands
Website: http://www.leiden.edu
Year Founded: 1575
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 14, 2024
Discovery & Translation
Science Spotlight: Reducing HIV load, new glycopeptide antibiotics, and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 22, 2022
Emerging Company Profile
With Medicxi’s backing, Vaderis taking industry’s first shot at rare vascular disorder
European VC’s series A investment to fund start-up’s clinical evaluation of AKT inhibitor for hereditary hemorrhagic telangiectasia
BioCentury | Jul 14, 2022
Emerging Company Profile
Hybridize: kidney-targeted RNA therapeutics
With backing from biotech vets Maraganore, van de Stolpe, Dutch newco is building a platform of kidney-targeted RNA therapies
BioCentury | Dec 22, 2021
Discovery & Translation
Grant jump-starts multinational stem cell initiative
Novo Nordisk Foundation commits €300M to consortium of institutions in Copenhagen, Leiden and Melbourne
BioCentury | Mar 25, 2021
Emerging Company Profile
Asher Bio: aiming cytokine therapies at specific immune cells
Emerging Company Profile: Asher Bio engineering cytokine specificity with Third Rock-led $55 million series A
BioCentury | Dec 29, 2020
Distillery Therapeutics
Optimized proline-based MENA inhibitors to treat breast cancer
DISEASE CATEGORY: Cancer
INDICATION: Breast cancer Small molecule inhibitors of the EVH1 domain of MENA, a cell migration protein, could treat breast cancer. Structure-based optimization of a
INDICATION: Breast cancer Small molecule inhibitors of the EVH1 domain of MENA, a cell migration protein, could treat breast cancer. Structure-based optimization of a
BioCentury | May 30, 2019
Company News
May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance
BioCentury | Aug 30, 2018
Targets & Mechanisms
Alt-neoantigens
Two studies tap a new vein of cancer neoantigens via alternative splicing
BioCentury | Aug 3, 2018
Targets & Mechanisms
Oxitope’s oxidation play
A UCSD group links oxidized lipids to atherosclerosis and spins out Oxitope Inc.
Items per page:
1 - 10 of 73